Vascular Disease in Scleroderma
暂无分享,去创建一个
[1] S. Kumar,et al. The TGF beta receptor endoglin in systemic sclerosis. , 2001, Asian Pacific journal of allergy and immunology.
[2] M. Conforti,et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.
[3] C. Ferri,et al. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? , 1996, The Journal of rheumatology.
[4] E. Colantuoni,et al. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. , 2009, Arthritis and rheumatism.
[5] B. Kahaleh. Vascular disease in scleroderma: mechanisms of vascular injury. , 2008, Rheumatic diseases clinics of North America.
[6] Y. Shoenfeld,et al. Heat‐Shock Protein 65 Autoantibodies Are Differently Associated with Early Atherosclerosis in Rheumatoid Arthritis and in Healthy Subjects , 2007, Annals of the New York Academy of Sciences.
[7] G. Mancia,et al. Effects of prostaglandin E1α cyclodestrin treatment on endothelial dysfunction in patients with systemic sclerosis , 2007 .
[8] S. Migliaresi,et al. Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. , 1995, Autoimmunity.
[9] V. Gurevich. Influenza, autoimmunity and atherogenesis. , 2005, Autoimmunity reviews.
[10] R Fleischmajer,et al. Capillary alterations in scleroderma. , 1980, Journal of the American Academy of Dermatology.
[11] M. Cutolo,et al. Nailfold video-capillaroscopy in systemic sclerosis , 2004, Zeitschrift für Rheumatologie.
[12] Oliver Distler,et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. , 2008, Arthritis and rheumatism.
[13] Michael Simons,et al. Antiangiogenic plasma activity in patients with systemic sclerosis. , 2007, Arthritis and rheumatism.
[14] C. Wiener,et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. , 2000, Arthritis and rheumatism.
[15] T. Medsger,et al. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. , 1989, The Journal of rheumatology.
[16] S. Flavahan,et al. Silent α2C-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries , 2000 .
[17] C. Penning,et al. Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. , 1984, Clinical and experimental immunology.
[18] Oliver Distler,et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. , 2007, Arthritis and rheumatism.
[19] V. Welch,et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. , 2001, Arthritis and rheumatism.
[20] T. Medsger,et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. , 1986, Arthritis and rheumatism.
[21] S. Marshall,et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. , 2001, Rheumatology.
[22] P. Woo,et al. Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. , 1988, Clinical and experimental immunology.
[23] T. Sycha,et al. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study , 2004, European journal of clinical investigation.
[24] P. Cannon,et al. THE RELATIONSHIP OF HYPERTENSION AND RENAL FAILURE IN SCLERODERMA (PROGRESSIVE SYSTEMIC SCLEROSIS) TO STRUCTURAL AND FUNCTIONAL ABNORMALITIES OF THE RENAL CORTICAL CIRCULATION , 1974, Medicine.
[25] R. Macko,et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. , 2002, The Journal of rheumatology.
[26] B. Bottasso,et al. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. , 1992, International journal of microcirculation, clinical and experimental.
[27] G. Burnstock,et al. Regulation of substance P mRNA expression in human dermal microvascular endothelial cells. , 2004, Clinical and experimental rheumatology.
[28] R. De Angelis,et al. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. , 2001, Scandinavian journal of rheumatology.
[29] S. Basili,et al. Autonomic dysfunction and microvascular damage in systemic sclerosis , 2007, Clinical Rheumatology.
[30] J. Morrow,et al. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. , 1996, Arthritis and rheumatism.
[31] G. Hutchins,et al. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. , 1978, American heart journal.
[32] G. Rodnan,et al. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. , 1980, Medicine.
[33] D. Collier,et al. Anticardiolipin antibodies in scleroderma. , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[34] S. Goland,et al. Effect of a single 20-mg tablet of Atorvastatin on brachial artery blood flow in normolipidemic male smokers versus nonsmokers. , 2007, The American journal of cardiology.
[35] J. Fries,et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. , 1969, The American journal of medicine.
[36] D. Borderie,et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. , 2008, Rheumatology.
[37] Leroy Ec,et al. Autoimmunity and Vascular Involvement in Systemic Sclerosis (SSc) , 1999 .
[38] M. Fujimoto,et al. A Clue for Telangiectasis in Systemic Sclerosis: Elevated Serum Soluble Endoglin Levels in Patients with the Limited Cutaneous Form of the Disease , 2006, Dermatology.
[39] J. Piette,et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. , 1998, The Journal of clinical investigation.
[40] N. Voelkel,et al. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.
[41] A. Merla,et al. Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. , 2007, The Journal of rheumatology.
[42] K. Takehara,et al. Elevated plasma endothelin levels in systemic sclerosis , 2004, Archives of Dermatological Research.
[43] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[44] M. Cutolo,et al. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients , 2007, Annals of the rheumatic diseases.
[45] D. Borderie,et al. Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis , 2004, Arthritis research & therapy.
[46] L. Hummers. Biomarkers of vascular disease in scleroderma. , 2008, Rheumatology.
[47] A. Zalewska,et al. Correlation of Endostatin and Tissue Inhibitor of Metalloproteinases 2 (TIMP2) Serum Levels With Cardiovascular Involvement in Systemic Sclerosis Patients , 2005, Mediators of inflammation.
[48] G. Wick,et al. Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (Scleroderma). , 2000, Journal of autoimmunity.
[49] J. Lekakis,et al. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. , 1998, The American journal of cardiology.
[50] Maricq Hr,et al. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. , 1982 .
[51] R. Abbate,et al. Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. , 2007, Rheumatology.
[52] J. Pearson,et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. , 1998, QJM : monthly journal of the Association of Physicians.
[53] B. Kahaleh. The microvascular endothelium in scleroderma. , 2008, Rheumatology.
[54] D. Abraham,et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. , 2001, The Journal of clinical investigation.
[55] R. Barst. PDGF signaling in pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.
[56] A. Kuryliszyn-Moskal,et al. A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis , 2006, Clinical Rheumatology.
[57] E. Hurd,et al. Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. , 1983, Arthritis and rheumatism.
[58] D. Ribatti,et al. Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane , 2005, Clinical Rheumatology.
[59] A. Freemont,et al. Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. , 1994, Annals of the rheumatic diseases.
[60] R. D. du Bois,et al. Exhaled nitric oxide is increased in active fibrosing alveolitis. , 1999, Chest.
[61] R. Fine. Cytotoxicity of sera from patients with scleroderma--effects on human endothelial cells and fibroblasts in culture. , 1984, International journal of dermatology.
[62] R. Koppensteiner,et al. Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon. , 2006, Clinical rheumatology.
[63] N. Sepp,et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. , 2000, Arthritis and rheumatism.
[64] M. Fujimoto,et al. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. , 1997, British journal of rheumatology.
[65] Leroy Ec,et al. Endothelial injury in scleroderma. A protease mechanism. , 1983 .
[66] M. Matucci-Cerinic,et al. Estrogens and neuropeptides in Raynaud's phenomenon. , 2005, Rheumatic diseases clinics of North America.
[67] C. Black,et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. , 2006, Rheumatology.
[68] A. Rosen,et al. Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis , 1997, The Journal of experimental medicine.
[69] C. Denton,et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. , 1999, Rheumatology.
[70] R. Koppensteiner,et al. Predictive value of naitfold capillaroscopy in patients with Raynaud’s phenomenon , 2006, Clinical Rheumatology.
[71] H. Maricq,et al. Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population. , 2006, Journal of vascular surgery.
[72] J. Murabito,et al. The incidence and natural history of Raynaud's phenomenon in the community. , 2005, Arthritis and rheumatism.
[73] M. Kahaleh,et al. Endothelial injury in scleroderma , 1979, The Journal of experimental medicine.
[74] M. Matucci-Cerinic,et al. Digital ulcers and outcomes assessment in scleroderma. , 2008, Rheumatology.
[75] E. Hachulla,et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. , 2007, The Journal of rheumatology.
[76] A. Freemont,et al. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. , 2006, Human pathology.
[77] H. Krasa,et al. Efficacy and tolerability of a selective α2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study , 2004 .
[78] C. Pearson,et al. Rheumatic disease sera reactive with capillaries in the mouse kidney. , 1972, Arthritis and rheumatism.
[79] B. Weill,et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. , 2005, Clinical and experimental rheumatology.
[80] M. Fujimoto,et al. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. , 1998, British journal of rheumatology.
[81] M. Greaves,et al. Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. , 1989, Clinical and experimental immunology.
[82] S. Jimenez,et al. Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[83] R. Barst,et al. Prostanoid therapy for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[84] A. Herrick,et al. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. , 2001, Clinical and experimental rheumatology.
[85] L. Andrade,et al. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. , 2007, Rheumatology.
[86] V. Fonollosa-Plá,et al. Anti-PDGFR-α antibodies measured by non-bioactivity assays are not specific for systemic sclerosis , 2008, Annals of the rheumatic diseases.
[87] K. Welsh,et al. Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. , 1996, The Journal of rheumatology.
[88] D. Abraham,et al. How does endothelial cell injury start? The role of endothelin in systemic sclerosis , 2007, Arthritis research & therapy.
[89] R. L. Linscheid,et al. Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5‐hydroxytryptamine , 1976, The British journal of dermatology.
[90] Francesco Boin,et al. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. , 2008, Arthritis and rheumatism.
[91] T. King,et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. , 2002, Rheumatology.
[92] D. Veale,et al. Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. , 1998, British journal of rheumatology.
[93] C. Savage,et al. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. , 1996, The Journal of clinical investigation.
[94] P. Bruneval,et al. Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS) , 2004, Archives of Dermatological Research.
[95] T. Medsger,et al. Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. , 1988, Arthritis and rheumatism.
[96] A. Blann,et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. , 1999, Arthritis and rheumatism.
[97] M. Cerinic,et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. , 2007, Arthritis and rheumatism.
[98] M. Cerinic,et al. Raynaud's phenomenon and vascular disease in systemic sclerosis. , 1999, Advances in experimental medicine and biology.
[99] A. Gabrielli,et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. , 2001, The Journal of rheumatology.
[100] M. Jayson,et al. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy , 1992, The British journal of dermatology.
[101] J. Cooke,et al. Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma , 2000, Vascular medicine.
[102] S. Yamazaki,et al. Cutaneous localization of endothelin‐1 in patients with systemic sclerosis: immunoelectron microscopic study , 1997, International journal of dermatology.
[103] H. Maricq,et al. Standstill of nailfold capillary blood flow during cooling in scleroderma and Raynaud's syndrome. , 1976, Blood vessels.
[104] R. Mason. Effects of calcium channel blockers on cellular apoptosis , 1999, Cancer.
[105] C. Denton,et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. , 1995, British journal of rheumatology.
[106] M. Jayson,et al. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin , 1999, The Journal of pathology.
[107] F. V. D. van den Hoogen,et al. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[108] S. Flavahan,et al. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. , 2005, American journal of physiology. Heart and circulatory physiology.
[109] K. Nishioka,et al. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. , 1998, The Journal of rheumatology.
[110] J. Varga,et al. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers , 2006, Expert opinion on pharmacotherapy.
[111] J. Weiss,et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. , 1986, Annals of internal medicine.
[112] K. Nishioka,et al. Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. , 1990, Journal of the American Academy of Dermatology.
[113] Tonia Moore,et al. Computerized nailfold video capillaroscopy--a new tool for assessment of Raynaud's phenomenon. , 2005, The Journal of rheumatology.
[114] P. Sfikakis,et al. Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. , 1993, Clinical immunology and immunopathology.
[115] J. Seibold,et al. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. , 1984, Arthritis and rheumatism.
[116] R. Sjogren,et al. Gastrointestinal motility disorders in scleroderma. , 1994, Arthritis and rheumatism.
[117] C. Bunker,et al. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon , 1993, The Lancet.
[118] M. Kahaleh,et al. Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. , 1997, Clinical immunology and immunopathology.
[119] J. Piette,et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. , 1997, The American journal of medicine.
[120] J. Egido,et al. Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent Mechanism , 2005, Circulation.
[121] Till Acker,et al. Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.
[122] N. Flavahan. Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon. , 2008, Rheumatic diseases clinics of North America.
[123] Walter Grassi,et al. Capillaroscopy: questions and answers , 2007, Clinical Rheumatology.
[124] X. Zheng,et al. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor β-receptor in fibroblasts of scleroderma , 1998 .
[125] S. Barnum,et al. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). , 2000, The Journal of rheumatology.
[126] R. Scorza,et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. , 2001, Clinical and experimental rheumatology.
[127] C. Black,et al. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. , 1995, Arthritis and rheumatism.
[128] A. Koch,et al. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis , 2007, Arthritis research & therapy.
[129] M. Vilardell,et al. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. , 1991, The Journal of rheumatology.
[130] T. Williams,et al. Cutaneous blood flow responses in the forearms of Raynaud's patients induced by local cooling and intradermal injections of CGRP and histamine. , 1990, British journal of clinical pharmacology.
[131] G. Hutchins,et al. A case–control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma) , 2006, Gut.
[132] Orris,et al. INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .
[133] C. Denton,et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis , 2007, Annals of the rheumatic diseases.
[134] A. Abidia. Endothelial Cell Responses To Hypoxic Stress , 2000, Clinical and experimental pharmacology & physiology.
[135] O. Kowal‐Bielecka,et al. The prevalence and clinical significance of antiphospholipid antibodies in the patients with systemic sclerosis--preliminary report. , 2005, Roczniki Akademii Medycznej w Bialymstoku.
[136] M. Cerinic,et al. Reduced circulating levels of angiotensin-(1–7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control , 2007, Annals of the rheumatic diseases.
[137] B. Roussel,et al. Anti-beta 2-glycoprotein I antibodies. , 1995, Clinical reviews in allergy & immunology.
[138] M. Simons,et al. Current concepts in normal and defective angiogenesis: Implications for systemic sclerosis , 2007, Current rheumatology reports.
[139] A. Freemont,et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.
[140] J. F. Wolfe,et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. , 1980, Arthritis and rheumatism.
[141] T. Koike,et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study , 2006, Annals of the rheumatic diseases.
[142] I. Goldstein,et al. Systemic sclerosis and impotence: a clinicopathological correlation. , 1995, The Journal of urology.
[143] B. Giusti,et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients , 2006, Arthritis research & therapy.
[144] M. Kahaleh,et al. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. , 1981, Annals of internal medicine.
[145] M. Gruschwitz,et al. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. , 1997, Arthritis and rheumatism.
[146] C. Junien,et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. , 2006, Rheumatology.
[147] M. Mayes,et al. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. , 1999, The Journal of rheumatology.
[148] L. Rudnicka,et al. Cytotoxic effects of sera from patients with systemic scleroderma: Comparison of three different in vitro methods , 2005, Rheumatology International.
[149] P. Helmbold,et al. Hyperplasia of dermal microvascular pericytes in scleroderma * , 2004, Journal of cutaneous pathology.
[150] W. Roberts,et al. Atherosclerotic Narrowing of the Left Main Coronary Artery: A Necropsy Analysis of 152 Patients with Fatal Coronary Heart Disease and Varying Degrees of Left Main Narrowing , 1976, Circulation.
[151] M. Harigai,et al. Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes. , 1999, The Journal of rheumatology.
[152] R. Gomer. Circulating progenitor cells and scleroderma , 2008, Current rheumatology reports.
[153] R. Fleischmajer,et al. [3H]Thymidine labeling of dermal endothelial cells in scleroderma. , 1977, The Journal of investigative dermatology.
[154] M. Böhm,et al. Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.
[155] M. Mayes,et al. Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma , 1999, The Lancet.
[156] N. Suzuki,et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. , 1992, The Journal of rheumatology.
[157] C. Stefanadis,et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. , 2007, Arthritis and rheumatism.
[158] A. Postlethwaite,et al. Platelet contributions to the pathogenesis of systemic sclerosis , 2007, Current opinion in rheumatology.
[159] C. Bunker,et al. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon , 1990, The Lancet.
[160] A. Gabrielli,et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. , 2006, Arthritis and rheumatism.
[161] A. Herrick,et al. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. , 1994, The Journal of rheumatology.
[162] B. Satiani,et al. Three cases of digital ischemia successfully treated with cilostazol , 2001, Vascular medicine.
[163] G. Damonte,et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells , 2000, Nature Medicine.
[164] J. Pope,et al. The frequency and significance of anticardiolipin antibodies in scleroderma. , 2000, The Journal of rheumatology.
[165] G. Hughes,et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. , 1997, British journal of rheumatology.
[166] H. Tse,et al. Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis , 2008, Clinical Rheumatology.
[167] J. Jespersen,et al. Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. , 1989, Scandinavian journal of rheumatology.
[168] H. Krasa,et al. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. , 2004, Arthritis & Rheumatism.
[169] M. Greaves,et al. Antibodies to membranes of endothelial cells and fibroblasts in scleroderma , 1996, Clinical and experimental immunology.
[170] Judy W. M. Cheng. Ambrisentan for the management of pulmonary arterial hypertension. , 2008, Clinical therapeutics.
[171] L. Klareskog,et al. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. , 1990, Arthritis and rheumatism.
[172] G. Pamuk,et al. Increased circulating platelet–leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[173] M. Mayes,et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.
[174] M. Cerinic,et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. , 2003, Seminars in arthritis and rheumatism.
[175] M. Pastor,et al. Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia. , 2003, Rheumatology.
[176] J. Egido,et al. Molecular mechanisms of angiotensin II-induced vascular injury , 2003, Current hypertension reports.
[177] Soo-Kon Lee,et al. Antiphospholipid Syndrome Associated with Progressive Systemic Sclerosis , 1996, The Journal of dermatology.
[178] H. Maricq,et al. Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. , 1973, Arthritis and rheumatism.
[179] James Allen,et al. The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. , 2007, American journal of clinical pathology.
[180] P. Altmeyer,et al. Macroangiopathy of the upper extremities in progressive systemic sclerosis. , 2000, European journal of medical research.
[181] S. Svegliati,et al. Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited , 2008, Seminars in Immunopathology.
[182] M. Sporn,et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[183] M. Petri,et al. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. , 2008, The Journal of rheumatology.
[184] L. Rudnicka,et al. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). , 1992, Arthritis & Rheumatism.
[185] C. Denton,et al. Angiographically proven coronary artery disease in scleroderma. , 2006, Rheumatology.
[186] T. Medsger,et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. , 1984, The New England journal of medicine.
[187] H. Maricq,et al. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. , 1982, The Journal of rheumatology.
[188] Y. Ikeda,et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. , 2006, Arthritis and rheumatism.
[189] T. King,et al. Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. , 2006, Arthritis and rheumatism.
[190] M. Mayes,et al. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. , 2001, The Journal of rheumatology.
[191] S. Rantapää-Dahlqvist,et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. , 2000, Arthritis and rheumatism.
[192] F. Ingegnoli,et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. , 2004, Arthritis and rheumatism.
[193] M. Greaves,et al. Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. , 1988, Clinical and experimental immunology.
[194] R. Barst,et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.
[195] Y. Konttinen,et al. Vascular damage and lack of angiogenesis in systemic sclerosis skin , 2003, Clinical Rheumatology.
[196] A. Kahan,et al. Increased nitric oxide in exhaled air in patients with systemic sclerosis. , 1998, Clinical and experimental rheumatology.
[197] B. Giusti,et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. , 2005, Arthritis and rheumatism.
[198] O. Hornstein,et al. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. , 1995, Arthritis and rheumatism.
[199] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[200] C. Denton,et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. , 2007, QJM : monthly journal of the Association of Physicians.
[201] D. Nowak,et al. Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis--association with pulmonary involvement. , 2006, Clinical and experimental rheumatology.
[202] H. Mizutani,et al. Increased endothelial and epidermal thrombomodulin expression and plasma thrombomodulin level in progressive systemic sclerosis. , 1996, Acta medica Okayama.
[203] S. Flavahan,et al. Rho Kinase Mediates Cold-Induced Constriction of Cutaneous Arteries: Role of &agr;2C-Adrenoceptor Translocation , 2004, Circulation research.
[204] Stephen M. Schwartz,et al. Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? , 2008, PloS one.
[205] Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.
[206] H. Sallam,et al. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma) , 2006, Alimentary pharmacology & therapeutics.
[207] A. Silman,et al. Factor VIII related antigen in connective tissue disease patients and relatives. , 1990, British journal of rheumatology.
[208] D. Veale,et al. Macrovascular disease and systemic sclerosis , 2000, Annals of the rheumatic diseases.
[209] H. Herzog,et al. Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons. , 1995, Canadian journal of physiology and pharmacology.
[210] L. Chung,et al. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. , 2006, Journal of the American Academy of Dermatology.
[211] J. Stockman,et al. Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2010 .
[212] A. Silman,et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. , 1998, The Cochrane database of systematic reviews.
[213] M. Nishimura,et al. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. , 2007, Circulation journal : official journal of the Japanese Circulation Society.
[214] R. Hesselstrand,et al. Simple counting of nailfold capillary density in suspected systemic sclerosis – 9 years' experience , 2007, Scandinavian journal of rheumatology.
[215] R. Benza,et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[216] J. Korn,et al. Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. , 1982, Arthritis and rheumatism.
[217] S. Jimenez,et al. Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? , 2006, Autoimmunity reviews.
[218] D. W. Johnson,et al. Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.
[219] T Moore,et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. , 1995, British journal of rheumatology.
[220] S. Yousem. The pulmonary pathologic manifestations of the CREST syndrome. , 1990, Human pathology.
[221] A. Gabrielli,et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.
[222] L. Mouthon,et al. Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). , 2006, Clinical immunology.
[223] M. Simons,et al. Vascular disease in scleroderma: angiogenesis and vascular repair. , 2008, Rheumatic diseases clinics of North America.
[224] V. Rajkumar,et al. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. , 1999, Arthritis and rheumatism.
[225] D. Judge,et al. Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.
[226] M. Roustit,et al. Abnormal digital neurovascular response to local heating in systemic sclerosis. , 2008, Rheumatology.
[227] M. Cerinic,et al. Vascular complications of scleroderma. , 2007, Autoimmunity reviews.
[228] L. Stafford,et al. Distribution of macrovascular disease in scleroderma , 1998, Annals of the rheumatic diseases.
[229] M. Kahaleh,et al. Human monocyte modulation of endothelial cells and fibroblast growth: possible mechanism for fibrosis. , 1986, Clinical immunology and immunopathology.
[230] M. Fujimoto,et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis , 2000, Clinical and experimental immunology.
[231] L. Kaufman,et al. Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study , 1994, Annals of Internal Medicine.
[232] C. Cho,et al. Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts , 2006, Clinical and experimental immunology.
[233] D. Knight,et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. , 2003, American journal of clinical pathology.
[234] J. Shaver,et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). , 1977, Annals of internal medicine.
[235] Malcolm D. Smith,et al. Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis , 2005, Pathology.
[236] E. Leroy. SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .
[237] K. Stengaard-Pedersen,et al. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. , 1998, British journal of rheumatology.
[238] K. Shaw,et al. Skin capillary changes in early systemic scleroderma. Electron microscopy and "in vitro" autoradiography with tritiated thymidine. , 1976, Archives of dermatology.
[239] C. Denton,et al. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. , 2000, Clinical and experimental rheumatology.
[240] A. Silman,et al. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. , 1998, The Cochrane database of systematic reviews.
[241] B. Weill,et al. Levels of circulating endothelial progenitor cells in systemic sclerosis. , 2007, Clinical and experimental rheumatology.
[242] A. Guttmacher,et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). , 2000, American journal of medical genetics.
[243] H. Shigemitsu,et al. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis , 2004, Current opinion in rheumatology.
[244] J. Catravas,et al. Pulmonary capillary endothelial dysfunction in early systemic sclerosis. , 2001, Arthritis and rheumatism.
[245] P. Merkel,et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. , 1996, The American journal of medicine.
[246] C. Kallenberg,et al. Diagnostic significance of nailfold capillary patterns in patients with Raynaud's phenomenon. An analysis of patterns discriminating patients with and without connective tissue disease. , 1986, The Journal of rheumatology.
[247] Hiroshi Watanabe,et al. Sildenafil for primary and secondary pulmonary hypertension , 2002, Clinical pharmacology and therapeutics.
[248] S. Gay,et al. Angiogenesis and vasculogenesis in systemic sclerosis. , 2006, Rheumatology.
[249] A. Brucato,et al. Anti-cardiolipin antibodies in progressive systemic sclerosis (PSS) , 1987, Clinical and experimental rheumatology.
[250] M. Cinelli,et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. , 2004, Arthritis and rheumatism.
[251] C. Daniels,et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.
[252] M. Kahaleh,et al. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. , 1982, Annals of internal medicine.
[253] M. Fujimoto,et al. Elevated circulating CD40L concentrations in patients with systemic sclerosis. , 2004, The Journal of rheumatology.
[254] A. Smit,et al. Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. , 1994, Seminars in arthritis and rheumatism.
[255] L. Fraenkel,et al. The Association of Estrogen Replacement Therapy and the Raynaud Phenomenon in Postmenopausal Women , 1998, Annals of Internal Medicine.
[256] R. Silver. Endothelin and scleroderma lung disease. , 2008, Rheumatology.
[257] G. Faccani,et al. Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. , 1984, Clinical and experimental rheumatology.
[258] H. Deicher,et al. Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus , 2004, Rheumatology International.
[259] G. Mancia,et al. Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. , 2007, Journal of hypertension.
[260] R. Wise,et al. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. , 1992, Arthritis and rheumatism.
[261] P. Furspan,et al. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. , 2004, Arthritis and rheumatism.
[262] Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. , 2008, Rheumatology.
[263] K. Yamane. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. , 1994, Internal medicine.
[264] M. Aringer,et al. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. , 1994, Clinical and experimental rheumatology.
[265] M. Rizzo,et al. [Digital ulcers in a cohort of 333 scleroderma patients]. , 2011, Reumatismo.
[266] G. Mark,et al. Pulmonary vascular changes in scleroderma. , 1978, The American journal of medicine.
[267] M. Baron,et al. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. , 2008, Arthritis and rheumatism.
[268] G. FitzGerald,et al. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. , 1986, British medical journal.
[269] A. Hasegawa,et al. Autopsy case of systemic sclerosis with severe pulmonary hypertension , 2007, Journal of dermatology (Print).
[270] P. Ryan,et al. Antiphospholipid syndrome in scleroderma. , 1993, Journal of Rheumatology.
[271] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[272] R. Silver,et al. Ulnar artery involvement in systemic sclerosis (scleroderma). , 2002, The Journal of rheumatology.
[273] J D Coffman,et al. Total and capillary fingertip blood flow in Raynaud's phenomenon. , 1971, The New England journal of medicine.
[274] J. van der Meer,et al. A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon. , 1987, VASA. Supplementum.
[275] M. Kahaleh,et al. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. , 1991, Arthritis and rheumatism.
[276] S. Flavahan,et al. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. , 2000, American journal of physiology. Heart and circulatory physiology.
[277] M. Cerinic,et al. Flow‐Mediated Vasodilation and Carotid Intima‐Media Thickness in Systemic Sclerosis , 2007, Annals of the New York Academy of Sciences.
[278] V. Fuster,et al. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. , 1984, Arthritis and rheumatism.
[279] I. Marie,et al. Anticardiolipin and anti‐β2 glycoprotein I antibodies and lupus‐like anticoagulant: prevalence and significance in systemic sclerosis , 2007, The British journal of dermatology.
[280] A. Blann,et al. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. , 2000, Clinical and experimental rheumatology.
[281] M. Jayson,et al. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. , 1993, The Journal of rheumatology.
[282] M. Ehrenfeld,et al. A Novel Overlap Syndrome , 2007, Annals of the New York Academy of Sciences.
[283] R. Moots,et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. , 2007, Arthritis and rheumatism.
[284] I M Braverman,et al. Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. , 1983, The Journal of investigative dermatology.
[285] O. Hornstein,et al. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. , 1992, Journal of the American Academy of Dermatology.
[286] W. L. Norton,et al. Vascular disease in progressive systemic sclerosis (scleroderma). , 1970, Annals of internal medicine.
[287] Y. Shoenfeld,et al. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. , 2003, Human Antibodies.
[288] S. Abou-Raya,et al. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. , 2008, The Journal of rheumatology.
[289] J. Johnson,et al. Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. , 1991, The Journal of investigative dermatology.
[290] L. Hornez,et al. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.
[291] M. Creager,et al. International study of ketanserin in Raynaud's phenomenon. , 1989, The American journal of medicine.
[292] V. Negi,et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. , 1998, The Journal of rheumatology.
[293] S. Bombardieri,et al. Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients. , 2008, Rheumatology.
[294] S. Schwartz,et al. The pathology of scleroderma vascular disease. , 2008, Rheumatic diseases clinics of North America.
[295] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[296] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[297] T. Medsger,et al. Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.
[298] A. Hobson,et al. Investigation of anal function in patients with systemic sclerosis. , 1996, Annals of the rheumatic diseases.
[299] G. Hunder,et al. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. , 1993, The Journal of rheumatology.
[300] M. Gershwin,et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. , 1996, The Journal of clinical investigation.
[301] M. Morfini,et al. Cutaneous and Plasma Fibrinolytic Activity in Systemic Sclerosis , 1990, International journal of dermatology.
[302] M. Matucci-Cerinic,et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. , 1998, Clinical and experimental rheumatology.
[303] P. Youssef,et al. Large vessel occlusive disease associated with CREST syndrome and scleroderma. , 1993, Annals of the rheumatic diseases.
[304] R. D. du Bois,et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. , 1997, Thorax.
[305] K. Csiszȧr,et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis , 2005, Arthritis research & therapy.
[306] N. Harris,et al. Microvascular responses following digital thermal hyperaemia and iontophoresis measured by laser Doppler imaging in idiopathic inflammatory myopathy. , 2007, Rheumatology.
[307] S. Sato,et al. Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis. , 2007, Clinical and experimental rheumatology.
[308] M. Kahaleh,et al. Endothelial injury in scleroderma. A protease mechanism. , 1983, The Journal of laboratory and clinical medicine.
[309] A. Sasseville,et al. Novel Fibrogenic Pathways Are Activated in Response to Endothelial Apoptosis: Implications in the Pathophysiology of Systemic Sclerosis1 , 2005, The Journal of Immunology.
[310] Y. Shoenfeld,et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications. , 2007, Rheumatology.
[311] B. S. Andrews,et al. The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. , 1988, Arthritis and rheumatism.
[312] P. Gosse,et al. Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study , 2007, Journal of hypertension.
[313] D. Pisetsky,et al. The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. , 2008, Arthritis and rheumatism.
[314] S. Jimenez,et al. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. , 1992, Arthritis and rheumatism.
[315] O. Meyer,et al. Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. , 1983, Clinical and experimental rheumatology.
[316] T. Medsger,et al. Hypertension and Renal Failure (Scleroderma Renal Crisis) in Progressive Systemic Sclerosis: REVIEW OF A 25‐YEAR EXPERIENCE WITH 68 CASES , 1983, Medicine.
[317] M. Tikly,et al. Lipid peroxidation and trace elements in systemic sclerosis , 2006, Clinical Rheumatology.
[318] H. Maricq,et al. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. , 1982, The American journal of medicine.
[319] S. Gay,et al. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement , 2004, Annals of the rheumatic diseases.
[320] J. Belch,et al. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation. , 1999, The Journal of rheumatology.
[321] E. Tan,et al. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. , 1983, Clinical and experimental rheumatology.
[322] R. Abbate,et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. , 2002, The American journal of medicine.
[323] A. Herrick,et al. Vascular function in systemic sclerosis , 2000, Current opinion in rheumatology.
[324] J. Lekakis,et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. , 1998, American heart journal.
[325] O. Hornstein,et al. Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts? , 1993, The Journal of investigative dermatology.
[326] W. Seeger,et al. Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[327] J. Tervaert,et al. Anti-endothelial cell antibodies in systemic sclerosis , 2010, Annals of the rheumatic diseases.
[328] Y. Ikeda,et al. Defective vasculogenesis in systemic sclerosis , 2004, The Lancet.
[329] E. Skopińska-Różewska,et al. Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. , 1986, The Journal of investigative dermatology.
[330] O. Ishikawa,et al. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis , 2006, The British journal of dermatology.
[331] J. Fiessinger,et al. Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. , 1982, Acta dermato-venereologica.
[332] H. Worthington,et al. Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. , 1996, The Journal of rheumatology.
[333] D. Scott,et al. Endothelial cell cytotoxicity in inflammatory vascular diseases--the possible role of oxidised lipoproteins. , 1985, Annals of the rheumatic diseases.
[334] D. W. Johnson,et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.
[335] Abraham,et al. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers , 1998, Clinical and experimental immunology.